Short Interest in The Chemours Company (NYSE:CC) Increases By 19.5%

The Chemours Company (NYSE:CC - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 10,530,000 shares, a growth of 19.5% from the February 28th total of 8,810,000 shares. Based on an average daily trading volume, of 2,500,000 shares, the short-interest ratio is currently 4.2 days. Approximately 7.1% of the company's stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CC. Charles Schwab Investment Management Inc. grew its position in shares of Chemours by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,229,052 shares of the specialty chemicals company's stock worth $24,974,000 after acquiring an additional 32,590 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Chemours during the 3rd quarter valued at about $728,000. Holocene Advisors LP grew its position in Chemours by 1,058.1% in the 3rd quarter. Holocene Advisors LP now owns 194,465 shares of the specialty chemicals company's stock worth $3,952,000 after purchasing an additional 177,673 shares during the last quarter. HighTower Advisors LLC grew its position in Chemours by 10.1% in the 3rd quarter. HighTower Advisors LLC now owns 15,020 shares of the specialty chemicals company's stock worth $300,000 after purchasing an additional 1,384 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Chemours in the third quarter valued at approximately $2,449,000. 76.26% of the stock is currently owned by institutional investors.

Chemours Stock Performance

CC stock traded down $0.10 during trading on Monday, hitting $10.53. 4,520,015 shares of the company's stock traded hands, compared to its average volume of 1,778,008. Chemours has a 52 week low of $9.68 and a 52 week high of $29.21. The stock has a fifty day moving average price of $15.49 and a two-hundred day moving average price of $17.95. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of 18.47 and a beta of 1.84.

Remove Ads

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The firm had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.37 billion. As a group, equities analysts anticipate that Chemours will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were given a dividend of $0.25 per share. The ex-dividend date was Friday, February 28th. This represents a $1.00 dividend on an annualized basis and a yield of 9.50%. Chemours's dividend payout ratio is currently 175.44%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CC shares. BMO Capital Markets decreased their price objective on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research report on Wednesday, February 19th. Mizuho upgraded Chemours from a "neutral" rating to an "outperform" rating and set a $19.00 price objective for the company in a research note on Thursday, March 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Barclays reduced their target price on Chemours from $19.00 to $16.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 1st. Finally, The Goldman Sachs Group dropped their price target on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $22.56.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.